Literature DB >> 12194991

Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer.

A Lopez-Beltran1, R J Luque, R Mazzucchelli, M Scarpelli, R Montironi.   

Abstract

A handful of traditional and newer therapeutic procedures, such as chemotherapy, immunotherapy, radiotherapy, photodynamic and laser treatment, and gene therapy, are used to treat epithelial malignancies of bladder origin. These treatment modalities, used either intravesically or systemically, produce morphological changes in the urothelial mucosa that can be mistaken for carcinoma. The pathologist must be able to separate toxic and drug related alterations from tumour related changes. The clinical history is usually invaluable in this assessment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12194991      PMCID: PMC1769754          DOI: 10.1136/jcp.55.9.641

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  81 in total

1.  Comparative analysis of DNA content in polyomavirus-infected urothelial cells, urothelial dysplasia and high grade transitional cell carcinoma.

Authors:  E M Wojcik; M C Miller; B C Wright; R W Veltri; G J O'Dowd
Journal:  Anal Quant Cytol Histol       Date:  1997-10       Impact factor: 0.302

2.  Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases.

Authors:  A Lopez-Beltran; A Pacelli; H J Rothenberg; P C Wollan; H Zincke; M L Blute; D G Bostwick
Journal:  J Urol       Date:  1998-05       Impact factor: 7.450

3.  Structural and ultrastructural changes in ileal neobladder mucosa: a 7-year follow-up.

Authors:  F Aragona; R De Caro; A Parenti; W Artibani; P Bassi; P F Munari; F Pagano
Journal:  Br J Urol       Date:  1998-01

4.  Holmium laser resection of bladder tumors (HoLRBT).

Authors:  A Das; P Gilling; M Fraundorfer
Journal:  Tech Urol       Date:  1998-03

Review 5.  Superficial bladder cancer: the role of interferon-alpha.

Authors:  A S Belldegrun; J R Franklin; M A O'Donnell; L G Gomella; E Klein; R Neri; U O Nseyo; T L Ratliff; R D Williams
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

6.  Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53.

Authors:  R J Cote; M D Dunn; S J Chatterjee; J P Stein; S R Shi; Q C Tran; S X Hu; H J Xu; S Groshen; C R Taylor; D G Skinner; W F Benedict
Journal:  Cancer Res       Date:  1998-03-15       Impact factor: 12.701

7.  Photodynamic effects of sulfonated aluminum chlorophthalocyanine in human urinary bladder carcinoma cells in vitro.

Authors:  M Müller; E Reich; U Steiner; R Heicappell; K Miller
Journal:  Eur Urol       Date:  1997       Impact factor: 20.096

8.  Local immune response after intravesical interferon gamma in superficial bladder cancer.

Authors:  N E Stavropoulos; E Ioachim; N Pavlidis; L Pappa; P Kalomiris; N J Agnantis
Journal:  Br J Urol       Date:  1998-06

9.  In vivo gene transfer methods in the bladder without viral vectors.

Authors:  K Harimoto; K Sugimura; C R Lee; K Kuratsukuri; T Kishimoto
Journal:  Br J Urol       Date:  1998-06

10.  A high prevalence of functional inactivation by methylation modification of p16INK4A/CDKN2/MTS1 gene in primary urothelial cancers.

Authors:  T Akao; Y Kakehi; N Itoh; E Ozdemir; T Shimizu; A Tachibana; M S Sasaki; O Yoshida
Journal:  Jpn J Cancer Res       Date:  1997-11
View more
  10 in total

1.  Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.

Authors:  Mandy L Y Sin; Kathleen E Mach; Rahul Sinha; Fan Wu; Dharati R Trivedi; Emanuela Altobelli; Kristin C Jensen; Debashis Sahoo; Ying Lu; Joseph C Liao
Journal:  Clin Cancer Res       Date:  2017-02-13       Impact factor: 12.531

2.  Diagnostically challenging cases: what are atypia and dysplasia?

Authors:  Joseph Sanfrancesco; J Stephen Jones; Donna E Hansel
Journal:  Urol Clin North Am       Date:  2013-02-26       Impact factor: 2.241

3.  Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer.

Authors:  Wilson Sui; Justin T Matulay; Ifeanyi C Onyeji; Marissa C Theofanides; Maxwell B James; Arindam RoyChoudhury; Sven Wenske; G Joel DeCastro
Journal:  World J Urol       Date:  2016-11-01       Impact factor: 4.226

Review 4.  Characteristics and clinical significance of histological variants of bladder cancer.

Authors:  Marco Moschini; David D'Andrea; Stephan Korn; Yasin Irmak; Francesco Soria; Eva Compérat; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

5.  Guizhi Fuling Wan as a Novel Agent for Intravesical Treatment for Bladder Cancer in a Mouse Model.

Authors:  Chi-Chen Lu; Cheng-Huang Shen; Chia-Bin Chang; Hsiao-Yen Hsieh; Jiann-Der Wu; Ling-Huei Tseng; Dennis W Hwang; Syue-Yi Chen; Shu-Fen Wu; Michael W Y Chan; Cheng-Da Hsu
Journal:  Mol Med       Date:  2016-01-13       Impact factor: 6.354

Review 6.  The optimal management of variant histology in muscle invasive bladder cancer.

Authors:  Raj Vikesh Tiwari; Nye Thane Ngo; Lui Shiong Lee
Journal:  Transl Androl Urol       Date:  2020-12

Review 7.  Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer-A Review.

Authors:  Jons W van Hattum; Ben-Max de Ruiter; Jorg R Oddens; Maarten C C M Hulshof; Theo M de Reijke; Adriaan D Bins
Journal:  Cancers (Basel)       Date:  2021-12-22       Impact factor: 6.639

Review 8.  Bladder Cancer Sample Handling and Reporting: Pathologist's Point of View.

Authors:  Roberta Mazzucchelli; Daniela Marzioni; Giovanni Tossetta; Laura Pepi; Rodolfo Montironi
Journal:  Front Surg       Date:  2021-12-02

9.  Synthesis, characterization, and biological activity of a triphenylphosphonium-containing imidazolium salt against select bladder cancer cell lines.

Authors:  Michael L Stromyer; Marie R Southerland; Uttam Satyal; Rahmat K Sikder; David J Weader; Jessi A Baughman; Wiley J Youngs; Philip H Abbosh
Journal:  Eur J Med Chem       Date:  2019-10-31       Impact factor: 7.088

10.  Effect of a Low Dose of Carvedilol on Cyclophosphamide-Induced Urinary Toxicity in Rats-A Comparison with Mesna.

Authors:  Anna Merwid-Ląd; Piotr Ziółkowski; Marta Szandruk-Bender; Agnieszka Matuszewska; Adam Szeląg; Małgorzata Trocha
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.